...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS >Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.
【24h】

Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen.

机译：在控制血浆病毒血症的患者中，总HIV-1 DNA和2个长末端重复循环的时程转换为含raltegravir的治疗方案。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Early integration of HIV proviral DNA into the host cell genome prevents viral eradication, despite suppressive HAART. In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia. PATIENTS AND METHODS: The EASIER-ANRS 138 randomized trial demonstrated that switching from enfuvirtide to raltegravir maintained virological suppression in treatment-experienced patients with viral load below 400 copies/ml. We analyzed total HIV-1 DNA and 2-LTR circle levels measured at weeks (W)0 and 24 in the first 30 patients enrolled in each arm, and at W48 in the raltegravir arm. RESULTS: At W0 the total DNA level was 3.6 log(10)/10(6) peripheral blood mononuclear cell (PBMC) in both groups, and 2-LTR circles were detected in six patients (median 89 copies/10(6) PBMC). At W24 the total DNA level was 3.6 log(10)/10(6) PBMC in both groups, and 2-LTR circles were detected in three new patients. At W48 the total HIV DNA level in the raltegravir group was 3.5 log(10)/10(6) PBMC, and 2-LTR circles were undetectable. No significant change in total HIV DNA occurred between W0 and W24 in either arm (P = 0.71) and no significant change was observed in the raltegravir arm at W48. DISCUSSION: In most patients on effective HAART, including regimens containing an integrase inhibitor, the viral reservoir, reflected by the HIV-1 DNA load, is stable and nondynamic during the 48 weeks of follow-up.
机译：背景：尽管具有抑制性的HAART，早期将HIV前病毒DNA整合入宿主细胞基因组仍可防止病毒根除。在体外，整合酶抑制剂可降低前病毒DNA的水平并迅速提高2-长端重复（LTR）环水平。我们检查了病毒性血友病患者中raltegravir对HIV-1 DNA形成时间过程的影响。患者和方法：EASIER-ANRS 138随机试验表明，在接受过治疗的病毒载量低于400拷贝/ ml的患者中，从恩夫韦肽转用raltegravir可以保持病毒学抑制作用。我们分析了在每个组招募的前30名患者在第（W）0和24周以及在raltegravir组的W48时测量的总HIV-1 DNA和2-LTR环水平。结果：在第0周时，两组的总DNA水平均为3.6 log（10）/ 10（6）外周血单个核细胞（PBMC），并且在6例患者中检测到2-LTR环（中位值为89拷贝/ 10（6）PBMC ）。在第24周，两组的总DNA水平均为3.6 log（10）/ 10（6）PBMC，并且在三名新患者中检测到2-LTR环。在第48周时，raltegravir组的总HIV DNA水平为3.5 log（10）/ 10（6）PBMC，并且未检测到2-LTR环。两组的W0和W24之间总HIV DNA均未发生显着变化（P = 0.71），而在第48周的raltegravir组中未观察到显着变化。讨论：在大多数接受有效HAART的患者中，包括含有整合酶抑制剂的治疗方案，在48周的随访中，HIV-1 DNA负荷反映出病毒库是稳定且无动力的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号